We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $62.28, making no change from the previous trading session. This change lagged the S&P 500's daily gain of 0.85%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 5.61%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.93% over the past month. This has lagged the Medical sector's loss of 1.55% and the S&P 500's gain of 3.18% in that time.
Bristol Myers Squibb will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2023. In that report, analysts expect Bristol Myers Squibb to post earnings of $2.04 per share. This would mark year-over-year growth of 5.7%. Our most recent consensus estimate is calling for quarterly revenue of $11.86 billion, down 0.2% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $8.05 per share and revenue of $46.55 billion. These results would represent year-over-year changes of +4.55% and +0.86%, respectively.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.1% lower within the past month. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.74. Its industry sports an average Forward P/E of 19.21, so we one might conclude that Bristol Myers Squibb is trading at a discount comparatively.
We can also see that BMY currently has a PEG ratio of 1.28. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.89 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know
Bristol Myers Squibb (BMY - Free Report) closed the most recent trading day at $62.28, making no change from the previous trading session. This change lagged the S&P 500's daily gain of 0.85%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 5.61%.
Prior to today's trading, shares of the biopharmaceutical company had lost 2.93% over the past month. This has lagged the Medical sector's loss of 1.55% and the S&P 500's gain of 3.18% in that time.
Bristol Myers Squibb will be looking to display strength as it nears its next earnings release, which is expected to be July 27, 2023. In that report, analysts expect Bristol Myers Squibb to post earnings of $2.04 per share. This would mark year-over-year growth of 5.7%. Our most recent consensus estimate is calling for quarterly revenue of $11.86 billion, down 0.2% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $8.05 per share and revenue of $46.55 billion. These results would represent year-over-year changes of +4.55% and +0.86%, respectively.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.1% lower within the past month. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.74. Its industry sports an average Forward P/E of 19.21, so we one might conclude that Bristol Myers Squibb is trading at a discount comparatively.
We can also see that BMY currently has a PEG ratio of 1.28. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.89 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.